Obermatt

JCR Pharmaceuticals

TYO:4552 · JP3701000006
PharmaceuticalsSmall

360

3
EV / EBIT5
Price / Owner Earnings80
Owner Earnings Yield1
Dividend Yield99
Price/Sales42
EV / Gross Profit46
Price/Book69
Return on Capital51
Cash Return on Capital44
Return on Equity67
EBIT Margin34
Gross Profitability69
Cash Conversion6
Accruals22
Owner Earnings Margin40
Sales growth6
Profit growth1
Reinvestment49
Price momentum50
Debt load11
Refinancing74
Debt Payback1
Liquidity26
Analyst ratings20
Opinion Changes50
Price Target Upside11
Market mood81
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

JCR Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryJapan
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTSE
Founded1975
Employees85
ISINJP3701000006
Last UpdateApr 2, 2026
Index & Theme
HematologyGeneticsStem Cell TherapyNeurologyCentral Nervous SystemGenetic DisorderBiopharmaBiotechnologyMedicalMedical DevicePharmaceutical

Description

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. Business Segments The co…

Analysis

Middle-of-the-road

JCR Pharmaceuticals Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is fragile. The company scores 13/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
20
2023202420252026

All-time high

44

Mar 2026

All-time low

4

Jan 2025

Average rank

25

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
42
54
32
20
Price/Earnings
30
53
49
47
Price/Book
69
69
38
16
Dividend Yield
99
84
51
34
Value (overall)
60
74
34
25

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare JCR Pharmaceuticals with its peers
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
SK Biopharmaceuticals
KSC:326030
87
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Hanall Biopharma
KSC:009420
30
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Daewoong Pharmaceutical
KSC:069620
27
CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Ildong Holdings
KSC:000230
83
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
CKD Bio
KSC:063160
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →